system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Cell Line, Tumor, Cell Proliferation, Cell Survival, Dose-Response Relationship, Drug, Estradiol, Humans, Male, Prostatic Neoplasms, Proteome, Proteomics, Selective Estrogen Receptor Modulators.
user
Does comparative proteomic analysis reveal growth inhibition by 3-N-alkyloxyestradiol derivative ( SERM ) in prostate cancer cells? Context: In this study we evaluated the proteomic profile of PC-3 cells treated with novel, 3-N-alkyloxyestradiol derivative, 3-[2-diisopropylamino]-ethoxy-D1,3,5 (10)-estrien-17-one (DI) (USPTO #7,687,486). The growth inhibitory potential of DI was determined by the National Cancer Institute (NCI) Developmental Therapeutics Program. 2-D gel electrophoresis and mass spectrometry were employed to identify differentially expressed proteins after treatment with DI. Growth inhibitory (GI(50)) results showed that DI inhibited the growth of PC-3 and DU-145 cells, at 13.9 μM and 30.8 μM, respectively. Out of the proteins differentially expressed, five were selected for identification with four of those being successfully identified. The identified proteins play a role in protein folding, cell motility, carbohydrate biosynthesis, and carbohydrate degradation.
assistant
Our studies resulted in the identification of targets associated with the glycolytic pathway and cell motility which have been implicated in the development and progression of many cancers. Final Decision: yes